{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:49:45Z","timestamp":1782197385396,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40265-026-02315-z","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:57:05Z","timestamp":1779350225000},"page":"1121-1132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial"],"prefix":"10.1007","volume":"86","clinical-trial-number":[{"clinical-trial-number":"nct05359068","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Qiang","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanquan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyue","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenliang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuntai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqing","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2315_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223\u201337. https:\/\/doi.org\/10.1038\/s41581-019-0244-2.","journal-title":"Nat Rev Nephrol"},{"key":"2315_CR2","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.117.032380","volume":"137","author":"Z Wang","year":"2018","unstructured":"Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, et al. Status of hypertension in China: results from the China Hypertension Survey, 2012\u20132015. Circulation. 2018;137:2344\u201356. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032380.","journal-title":"Circulation"},{"key":"2315_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ijcard.2021.01.070","volume":"331","author":"G Parati","year":"2021","unstructured":"Parati G, Lombardi C, Pengo M, Bilo G, Ochoa JE. Current challenges for hypertension management: from better hypertension diagnosis to improved patients\u2019 adherence and blood pressure control. Int J Cardiol. 2021;331:262\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2021.01.070.","journal-title":"Int J Cardiol"},{"key":"2315_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000249","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Writing Committee Members*, et al. AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension [Internet]. 2025. https:\/\/doi.org\/10.1161\/HYP.0000000000000249.","journal-title":"Hypertension [Internet]"},{"key":"2315_CR5","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/S0140-6736(19)32317-7","volume":"394","author":"MA Suchard","year":"2019","unstructured":"Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(19)32317-7.","journal-title":"Lancet"},{"key":"2315_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1524-6175.2007.07125.x","volume":"9","author":"CVS Ram","year":"2007","unstructured":"Ram CVS. Direct renin inhibitors: a new approach to antihypertensive drug treatment. J Clin Hypertens. 2007;9:615\u201321. https:\/\/doi.org\/10.1111\/j.1524-6175.2007.07125.x.","journal-title":"J Clin Hypertens"},{"key":"2315_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178312","volume":"1008","author":"A De","year":"2025","unstructured":"De A, Calcutta A, Della Pietra GP, Loffredo D, Vigilante R, Di Paola R, et al. Potential role of Aliskiren in cancer modulation compared to other Renin-Angiotensin inhibitors: an in-depth review. Eur J Pharmacol. 2025;1008:178312. https:\/\/doi.org\/10.1016\/j.ejphar.2025.178312.","journal-title":"Eur J Pharmacol"},{"key":"2315_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13318-019-00573-9","volume":"45","author":"L Zhang","year":"2020","unstructured":"Zhang L, Mao Y, Gao Z, Chen X, Li X, Liu Y, et al. The nonclinical pharmacokinetics and prediction of human pharmacokinetics of SPH3127, a novel direct renin inhibitor. Eur J Drug Metab Pharmacokinet. 2020;45:15\u201326. https:\/\/doi.org\/10.1007\/s13318-019-00573-9.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2315_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2019.104484","volume":"109","author":"Y Mao","year":"2019","unstructured":"Mao Y, Zhang L, Li H, Li X, Liu Y, Xia G. Evaluation of preclinical safety profile of SPH3127, a direct renin inhibitor, after 28-day repeated oral administration in Sprague-Dawley rats and cynomolgus monkeys. Regul Toxicol Pharmacol. 2019;109:104484. https:\/\/doi.org\/10.1016\/j.yrtph.2019.104484.","journal-title":"Regul Toxicol Pharmacol"},{"key":"2315_CR10","doi-asserted-by":"publisher","first-page":"735.e1","DOI":"10.1016\/j.clinthera.2021.01.025","volume":"43","author":"S Jing","year":"2021","unstructured":"Jing S, Xu R, Yang K, Liu W, Zhang L, Ke Y, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of SPH3127: a phase I, randomized, double-blind, placebo-controlled trial. Clin Ther. 2021;43:735.e1-735.e14. https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.025.","journal-title":"Clin Ther"},{"key":"2315_CR11","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/s41440-024-01657-z","volume":"47","author":"F Wang","year":"2024","unstructured":"Wang F, Liu L, Ruan H, Chen X, Zhang Y, Yu Z, et al. A randomized, double-blind, placebo-controlled, phase IIa, clinical study on investigating the efficacy and safety of SPH3127 tablet in patients with essential hypertension. Hypertens Res. 2024;47:1925\u201333. https:\/\/doi.org\/10.1038\/s41440-024-01657-z.","journal-title":"Hypertens Res"},{"key":"2315_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.11909\/j.issn.1671-5411.2019.03.014","volume":"16","author":"Joint Committee for Guideline Revision","year":"2019","unstructured":"Joint Committee for Guideline Revision. 2018 Chinese guidelines for prevention and treatment of hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol. 2019;16:182\u2013241. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2019.03.014.","journal-title":"J Geriatr Cardiol"},{"key":"2315_CR13","doi-asserted-by":"publisher","DOI":"10.31546\/2633-7916.1009","volume":"2","author":"JK Kim","year":"2020","unstructured":"Kim JK, Crimmins EM. Blood pressure and mortality: Joint effect of blood pressure measures. J Clin Cardiol Cardiovasc Ther. 2020;2:1009. https:\/\/doi.org\/10.31546\/2633-7916.1009.","journal-title":"J Clin Cardiol Cardiovasc Ther"},{"key":"2315_CR14","unstructured":"Khalil H, Zeltser R. Antihypertensive Medications. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Dec 18]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554579\/. Accessed 18 Dec 2025."},{"key":"2315_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.amjmed.2007.11.016","volume":"121","author":"MM Shafiq","year":"2008","unstructured":"Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med. 2008;121:265\u201371. https:\/\/doi.org\/10.1016\/j.amjmed.2007.11.016.","journal-title":"Am J Med"},{"key":"2315_CR16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with Sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(18)30351-6.","journal-title":"Lancet Oncol"},{"key":"2315_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/01.hjh.0000202812.72341.99","volume":"24","author":"M Azizi","year":"2006","unstructured":"Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with Aliskiren: where are we now, and where are we going? J Hypertens. 2006;24:243\u201356. https:\/\/doi.org\/10.1097\/01.hjh.0000202812.72341.99.","journal-title":"J Hypertens"},{"key":"2315_CR18","first-page":"343","volume":"63","author":"V Gerc","year":"2009","unstructured":"Gerc V, Buksa M, Loza V, Kulic M. Is Aliskiren superior to inhibitors of Angiotensin-converting enzyme and Angiotensin receptor blockers in Renin-Angiotensin System blockade? Med Arh. 2009;63:343\u20139.","journal-title":"Med Arh"},{"key":"2315_CR19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/ajh.2011.3","volume":"24","author":"D Gao","year":"2011","unstructured":"Gao D, Ning N, Niu X, Wei J, Sun P, Hao G. Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials. Am J Hypertens. 2011;24:613\u201321. https:\/\/doi.org\/10.1038\/ajh.2011.3.","journal-title":"Am J Hypertens"},{"key":"2315_CR20","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1161\/HYPERTENSIONAHA.108.110932","volume":"51","author":"J Nussberger","year":"2008","unstructured":"Nussberger J, Aubert J-F, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by Aliskiren prevents atherosclerosis progression: comparison with Irbesartan, Atenolol, and Amlodipine. Hypertension. 2008;51:1306\u201311. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.110932.","journal-title":"Hypertension"},{"key":"2315_CR21","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/eurheartj\/ehu079","volume":"35","author":"KK Teo","year":"2014","unstructured":"Teo KK, Pfeffer M, Mancia G, O\u2019Donnell M, Dagenais G, Diaz R, et al. Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. Eur Heart J. 2014;35:1743\u201351. https:\/\/doi.org\/10.1093\/eurheartj\/ehu079.","journal-title":"Eur Heart J"},{"key":"2315_CR22","unstructured":"Drug Approval Package [Internet]. [cited 2025 Dec 18]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/021985s000TOC.cfm. Accessed 18 Dec 2025."},{"key":"2315_CR23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/00004872-199609000-00016","volume":"14","author":"NJ Holwerda","year":"1996","unstructured":"Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, et al. Valsartan, a new Angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and Enalapril. J Hypertens. 1996;14:1147\u201351. https:\/\/doi.org\/10.1097\/00004872-199609000-00016.","journal-title":"J Hypertens"},{"key":"2315_CR24","unstructured":"Guideline on Non-Inferiority Clinical Trials for Drugs released by the Center for Drug Evaluation (CDE) of China. 2020; https:\/\/www.cde.org.cn\/main\/att\/download\/0a09abf034432ed0b35836e27ffeb6bc. Accessed 18 Dec 2025."},{"key":"2315_CR25","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3892\/etm.2017.4051","volume":"13","author":"N Sun","year":"2017","unstructured":"Sun N, Feng Y, Gao P, Chen X, Qi L, Zhang S, et al. Efficacy and tolerability of once-daily 160 mg Valsartan in Chinese patients with mild to moderate hypertension. Exp Ther Med. 2017;13:1109\u201316. https:\/\/doi.org\/10.3892\/etm.2017.4051.","journal-title":"Exp Ther Med"},{"key":"2315_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.jhh.1000788","volume":"13","author":"JL Pool","year":"1999","unstructured":"Pool JL, Glazer R, Chiang YT, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens. 1999;13:275\u201381. https:\/\/doi.org\/10.1038\/sj.jhh.1000788.","journal-title":"J Hum Hypertens"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02315-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02315-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02315-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:39:29Z","timestamp":1782196769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02315-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2315"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02315-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yuanyuan Cao, Yaohua Huang, Yue Zhang, Weiwei Cui are employees of Shanghai Pharmaceutical Holding Co., Ltd. All the other authors have no conflicts of interest regarding the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Substantially contributed to conception or design: Qiang Lv, Changsheng Ma,\u00a0Contributed to subject enrolment and data collection:\u00a0Qiang Lv, Fang Wang, Lipeng\u00a0Li, Gang Xiong, Zhanquan Li, Yanling Qu, Wenyue Pang, Wenliang Xiao, Hongyun Ruan, Liping Wei, Gang Liu, Jun Zhang, Qiong Liu, Ling Lin, Mingzhi Long, Huanming Li, Hong Yuan, Ling Liu, Yue Gao, Peijing Liu, Cuntai Zhang, Zhirong Wang, Jianhong Xie, Jiguang Wang, Xin Zhang, Yongyi Lu, Kai Huang, Min Liu, Jiyan Chen, Xiaohong Gao, Dongfang Wang, Xueping Ma, Xiaoping Chen, Yuhui Li, Yue Zhang, Xiangqing Kong, Fang Chen, Xiaowei Zhang, Jie Qi; Contributed to the acquisition, analysis, or interpretation of data: Yaohua Huang;\u00a0Drafted the manuscript content: Yue Zhang, Weiwei Cui; Critically revised the manuscript for important intellectual content: Qiang Lv, Changsheng Ma, Yuanyuan Cao; Gave final approval: all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"This study was approved by Beijing Anzhen Hospital Clinical Research Ethics Committee, Approval No:2021-004D.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All participants signed written informed consent to participate in the trial before screening.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}